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Background/aim: Nonalcoholic fatty liver disease (NAFLD) is known as the most common cause of chronic liver disease. It is accepted
that the leading cause of death in patients with NAFLD is from coronary events. Blood urea nitrogen (BUN) was used as a prognostic
indicator for cardiovascular disease. We aimed to investigate the relationship between BUN levels and metabolic, biochemical, and
histopathologic findings of nondiabetic patients with NAFLD.
Materials and methods: A total of 195 male patients with biopsy proven NAFLD and 82 healthy controls with normal liver and renal
function tests and normal abdominal ultrasonography were enrolled in the study. BUN levels were reviewed retrospectively.
Results: The mean BUN levels of patients and controls were 13.07 (11.3–15.41) and 13.31 (10.97–15.87) mg/dL respectively. Patients were
grouped as simple steatosis (n = 33, 16.9%), borderline nonalcoholic steatohepatitis (n = 64, 32.8%), and nonalcoholic steatohepatitis
(n = 98, 50.3%), and the BUN levels of the histologic subgroups were 13.14 ± 2.89, 14.34 ± 3.04, and 13.71 ± 3.21 mg/dL, respectively.
We could not find any differences between the patient group and control group with respect to BUN levels.
Conclusion: Our findings showed that there was no relationship between BUN levels and metabolic, biochemical, and histopathologic
findings of patients with NAFLD. Further investigations, including in patients with late stages of NAFLD, are required.
Key words: Nonalcoholic fatty liver disease, blood urea nitrogen, insulin resistance

1. Introduction
Nonalcoholic fatty liver disease (NAFLD) is accepted
as the most common cause of chronic liver disease.
NAFLD represents a spectrum of varying severity of liver
disease, ranging from simple steatosis to nonalcoholic
steatohepatitis (NASH), coexistent inflammation with
hepatocyte ballooning and necrosis, variable grades
of fibrosis, and ultimately cirrhosis. Also the patients
with cirrhosis related to NAFLD have increased risk of
hepatocellular carcinoma (1,2).
NAFLD is defined as the liver part of metabolic
syndrome (MetS), and insulin resistance (IR), dyslipidemia,
and obesity, key features of the MetS, are strongly associated
with NAFLD progression (3). Moreover, it is shown that
with the development of NASH, the degree and severity of
cardiovascular disease (CVD) becomes directly proportional
to the amount of inflammation on liver biopsy. NASH carries
a higher risk of CVD and mortality than simple steatosis
* Correspondence: cnercin@hotmail.com

(4,5). In light of the data published in the past several years,
it is accepted that the leading cause of death in patients with
NAFLD is from coronary events (6–9).
In patients with heart failure (HF), it is shown that
increases in blood urea nitrogen (BUN) are associated
with increased in-hospital, short-, and intermediate term
mortality (10,11). BUN elevation is probably a result of
the renal response to systemic hypoperfusion and BUN
levels may represent the cumulative effects of several
influences, including hemodynamic alterations that result
in renal hypoperfusion, neurohormonal activation that is
closely associated with altered renal hemodynamics. The
main part of this neurohormonal activation is the reninangiotensin-aldosterone system (RAAS), and BUN may be
accepted as a marker of neurohormonal activation in the
setting of HF (12).
There are limited data about the relationship
between NAFLD and BUN as a prognostic indicator
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for cardiovascular disease. Therefore, in the present
study we investigated the BUN levels in nondiabetic and
nonhypertensive patients with biopsy proven NAFLD.
2. Materials and methods
We retrospectively analyzed our database between 2007
and 2012 and identified all adult patients diagnosed with
histologically proven NAFLD. This study was approved
by the Research Ethics Committee of Gulhane School of
Medicine in accordance with the Helsinki II Declaration.
2.1. Study population
The study population consisted of 195 male patients who
were diagnosed during a periodic health examination and
results were obtained from a cohort of young male NAFLD
patients. Inclusion criteria were: persistently (at least 6
months) elevated liver enzymes (aminotransferases),
liver biopsy confirmed NAFLD, negative test results
for hepatitis B and C infection and other causes of liver
disease (autoimmune liver disease, Wilson’s disease,
hemochromatosis, α1-antitrypsin deﬁciency, etc.), less
than 20 g of alcohol intake per day, no medication use
known to increase fat deposition in the liver such as
nucleoside analogues, methotrexate, and amiodarone.
Subjects with hypertension and/or type 2 diabetes mellitus
(T2DM) were excluded from the study. Liver biopsies were
performed between 2007 and 2012 as part of investigation
of abnormal liver function tests, or to stage disease severity,
in subjects with radiologically confirmed NAFLD.
The control group consisted of 82 male healthy controls
with normal liver and renal function tests and normal
abdominal ultrasonography.
2.2. Clinical examination
All attendees underwent a routine standardized medical
history and physical examination (including blood
pressure measurement), anthropometry, and laboratory
assessment of fatty liver risk factors. Height, weight, waist
circumference (WC; midway between the lowest rib and
the iliac crest at the end of normal expirium), and body
mass index (BMI; the weight in kilograms divided by the
square of the height in meters, kg/m2) were measured and
calculated by trained research assistants.
2.3. Laboratory assessment
Blood samples were collected into Vacutainer tubes
by venipuncture after a fasting period of at least 10 h
and serum samples were separated for the analysis of
the biochemical parameters without freezing. Alanine
aminotransferase (ALT), aspartate aminotransferase
(AST), γ-glutamyltransferase (GGT), triglyceride (TG),
total cholesterol (TC), high-density lipoprotein cholesterol
(HDL-C), fasting plasma glucose (FPG), creatinine, and
uric acid (UA) levels were measured by the enzymatic
colorimetric total bilirubin, indirect bilirubin, urea
methods with Olympus AU2700 (Beckman Coulter) auto
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analyzer by using commercially available reagents. The
BUN level as mg/dL was calculated by multiplying the urea
level by 0.467. Since the direct low-density lipoprotein
cholesterol (LDL-C) measurement is expensive in patients
with triglycerides under 400 mg/dL, as in our patients, it
was estimated using the Friedewald formula (13). Fasting
serum insulin concentrations were measured by an ADVIA
Centaur assay (Siemens Medical Solutions Diagnostics)
with a sensitivity of 0.5 µU/L, and intraassay and interassay
CV of 4.6% and 5.9%, respectively. The Homeostasis
Model Assessment of Insulin Resistance (HOMA-IR) was
calculated as the product of fasting serum insulin (mU/L)
and FPG (mmol/L) divided by 22.5 (14).
2.4. Liver histology
A single experienced liver pathologist, blinded to the
patients’ details, reviewed the histology slides to confirm
the diagnosis of NAFLD for all subjects. Histopathological
variables were scored according to the NASH Clinical
Research Network Scoring System (15). Steatosis was
graded as none, mild, moderate, and severe (0–3); lobular
inflammation was graded according to the number of
inflammatory foci per 200× field (0 is no foci; 1 is <2 foci
per 200× field, 2 is 2–4 foci per 200× field, 3 is >4 foci per
200× field); hepatocellular ballooning was graded as none,
few balloon cells, and many cells/prominent ballooning (0–
2); Mallory’s hyaline was graded as none to rare, and many
(0–1). The stage of fibrosis was scored on a five-point scale,
as follows: stage 0 = no fibrosis, stage 1 = perisinusoidal
or periportal fibrosis, stage 2 = perisinusoidal and portal/
periportal fibrosis, stage 3 = bridging fibrosis, and stage 4
= cirrhosis. The NAFLD Score (NAS) was calculated as the
unweighted sum of steatosis, lobular inflammation, and
hepatocellular ballooning scores. According to this, cases
with NAS of 0–2 were considered to be simple steatosis
(SS), cases with activity scores of 3 and 4 were considered
as borderline NASH, and scores of ≥5 were diagnosed as
NASH.
2.5. Statistical analysis
All statistical analyses were performed using the SPSS
for Windows v. 15. Demographical, biochemical, and
histological features were classified as continuous or
categorical variables. Kolmogorov–Smirnov analysis was
used to test for Gaussian distribution. For Gaussiandistributed variables, the data were expressed as arithmetic
means ± standard deviation (SD). For those variables that
were not Gaussian distributed, the data were expressed
as median (25th–75th interquartile range). Comparisons
among groups were performed by using one-way ANOVA
with the Bonferroni all-pair-wise multiple comparison or
Kruskal–Wallis variance analysis with Mann–Whitney
U test comparison, as appropriate. All reported P values
were two-tailed, and those less than 0.05 were considered
significant.
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3. Results
Comparison of anthropometric and laboratory features of
patients with NAFLD and controls are shown in Table 1.
The mean BUN levels of patients and controls were 13.07
(11.3–15.41) and 13.31 (10.97–15.87) mg/dL respectively,
and no difference was found regarding the BUN levels
between the two groups.
Histopathological findings of the study participants are
shown in Table 2. Patients were grouped as SS, borderline
NASH, and NASH. There were 33 patients (16.9%) with
SS, 64 patients (32.8%) with borderline NASH, and 98
patients (50.3%) with NASH. Group-wise comparisons
showed that NASH, borderline NASH, and SS patients
have a significantly higher BMI, WC, FPG, TC, HDL-C,
LDL-C, AST, ALT, GGT, HOMA-IR, and insulin levels
than the controls (P < 0.05). On the other hand, no

significant difference was found regarding BUN levels
among different histologic subgroups (Table 3).
Comparison of anthropometric and laboratory features
of patients with (n = 107) and without (n = 88) fibrosis are
shown in Table 4. Both groups were comparable regarding
age, BMI, WC, FPG, lipid parameters, and GGT. AST, ALT,
and HOMA-IR were significantly higher in patients with
fibrosis than in patients without fibrosis (p < 0.001, P =
0.001, and P = 0.003, respectively). On the other hand,
no significant difference was found regarding BUN levels
among patients with and without fibrosis (Table 4).
We also performed correlation analyses for associations
of BUN levels with anthropometric, laboratory, and
histopathological findings in NAFLD group. BUN levels
were positively associated with TC (r = 0.127, P = 0.039)
and TG (r = 0.199, P = 0.001) levels.

Table 1. Comparison of anthropometric and laboratory features of patients with non-alcoholic fatty liver disease and controls.
Variable

NAFLD (n = 195)

Controls (n = 82)

P value

Age (years)

32 ± 6

29 ± 5

<0.001

BMI (kg/m )

28.7 ± 3

23.9 ± 2.7

<0.001

WC (cm)

100 (96–104)

86 (82–90)

<0.001

FPG (mg/dL)

94 (87–99)

81 (74–90)

<0.001

TC (mg/dL)

205 ± 46

177 ± 32

<0.001

TG (mg/dL)

160 (122–245)

99 (72–139)

<0.001

HDL-C (mg/dL)

40 (37–45)

46 (39–53)

<0.001

LDL-C (mg/dL)

128 ± 38

108 ± 30

<0.001

AST (IU/L)

48 (37–61)

20 (17–24)

<0.001

ALT (IU/L)

102 (73–130)

18 (12–26)

<0.001

GGT (IU/L)

57(41–79)

20 (17–26)

<0.001

Üre (mg/dL)

28 (24–33)

29 (24–34)

0.419

BUN (mg/dL)

13.07 (11.3–15.41)

13.31 (10.97–15.87)

0.399

Creatinine (mg/dL)

1.05 (0.99–1.12)

1.03 (0.93–1.11)

0.698

GFR (mL/min/1.73 m2)

89.82 ± 12.31

91.16 ± 11.2

0.414

Albumin (mg/dL)

4.8 ± 0.3

4.7 ± 0.3

0.400

Insulin (µU/mL)

13.76 (9.92–19.41)

6.24 (4.15–9.05)

<0.001

HOMA-IR

2.48 (1.41–4.34)

1.02 (0.61–1.61)

<0.001

2

Data are expressed as means ± SD or median (25th–75th interquartile range) as appropriate.
NAFLD: nonalcoholic fatty liver disease, BMI: body mass index, WC: waist circumference, FPG: fasting plasma glucose, TC: total
cholesterol, TG: triglyceride, HDL-C: high density lipoprotein cholesterol, LDL-C: low density lipoprotein cholesterol, AST: aspartate
aminotransferase, ALT: alanine aminotransferase, GGT: γ-glutamyltransferase, BUN: blood urea nitrogen, GFR: glomerular filtration
rate, HOMA-IR: homeostasis model of assessment-insulin resistance.
Values in bold are significant.
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Table 2. Histological features of patients with non-alcoholic fatty
liver disease
Histology (n =195)
NAS, n (%)
0–2

33 (16.9 %)

3–4

64 (32.8 %)

5–8

98 (50.3 %)

Lobular inflammation, n (%)
0

11 (5.6 %)

1

108 (55.4 %)

2

75 (38.5 %)

3

1 (0.5 %)

Steatosis, n (%)
0

8 (4.1 %)

1

57 (29.2 %)

2

84 (43.1 %)

3

46 (23.6 %)

Hepatocellular ballooning, n (%)
0

31 (15.9 %)

1

124 (63.6 %)

2

40 (20.5 %)

Fibrosis, n (%)
0

88 (45.1 %)

1

98 (50.3 %)

2

7 (3.6 %)

3

2 (1.0 %)

Data are expressed as the number of cases (%).
NAFLD: nonalcoholic fatty liver disease, NAS: NAFLD activity
score.

4. Discussion
To our knowledge, this is the first study addressing
the relationship between BUN and NAFLD in patients
diagnosed by liver biopsy. We did not find a significant
difference between either in the subgroups of NAFLD
or in patients with NAFLD and the control group with
respect to the BUN levels. BUN levels were correlated with
TC and TG levels.
Urea serves an important role in the metabolism
of nitrogen-containing compounds and is the main
nitrogen-containing substance in the urine. In the absence
of conditions that enhance urea production, such as
gastrointestinal bleeding, corticosteroid therapy, or a highprotein diet, elevations in BUN levels are often due to a
decrease in glomerular filtration rate (16). It is shown that
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in chronic cardiovascular diseases, the elevation of BUN
is related to mortality; the active RAAS and the nervous
system play important roles in this process (17). In a study
performed by O’Connor et al. (18), high BUN levels were
found to be the strongest predictor of short term mortality
in patients with acute heart failure (HF); moreover, lower
serum albumin, cholesterol, and systolic blood pressure
were other independent predictors of this worst outcome.
In another study, higher concentrations of BUN, serum
creatinine, and lower serum albumin and TC levels were
demonstrated to be a marker for hospital death in older
patients with severe, acute HF. Because albumin and TC
are accepted as biomarkers of malnutrition-inflammation
syndrome, abnormal concentrations of these two
biomarkers are common in elderly patients with acute
HF (19). In the present study BUN levels were positively
correlated with TC and TG levels. We suggest that this
positive correlation may make researchers think of BUN
as a prognostic indicator for cardiovascular disease.
Insulin resistance (IR) plays a central role in
the pathophysiology of NAFLD. We learned from
experimental studies that there was a close relationship
between insulin signaling and RAAS, resulting in
the worsening of IR (20). Angiotensin II induces the
generation of reactive oxygen species by activating the
nicotinamide adenine dinucleotide phosphate oxidase and
regulates the production of proinflammatory mediators,
including tumor necrosis factor α, interleukin-6, and PAI1. This results in impairment of insulin signaling (21,22).
It was shown that as the primary effector of the physiologic
outcomes of RAAS signaling, Angiotensin II takes part in
the development and progression of NAFLD, including
increased steatosis, inflammation, insulin resistance,
and fibrosis (23). Additionally, data from both animal
and human studies indicate that RAAS plays a key role
in hepatic fibrosis by activation of hepatic stellate cells,
upregulation of proinflammatory/profibrotic cytokines,
and induction of oxidative stress (24). We did not find a
significant difference between patients with and without
fibrosis regarding the BUN levels. However, studies
including patients with late stage fibrosis may shed more
light on this issue.
There is one previous study in which the value of BUN
in patients with NAFLD was investigated (25). In that
study, the NAFLD diagnosis was based on blood testing,
ultrasound imaging, and liver/spleen ratio of computed
tomography values. These imaging modalities can give only
information about the steatosis. ALT alone is not an ideal
marker for either diagnosis of NAFLD or distinguishing
steatosis from NASH (26). Researchers used AST and ALT
levels to estimate inflammation. There was no information
about the fibrosis level of the patient, which is related to
the activation of RAAS. They found that BUN levels in
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Table 3. Comparison of anthropometric and laboratory features of patients with SS, borderline NASH, NASH, and controls.
Variable

NASH
(n = 98)

Borderline
(n = 64)

SS
(n = 33)

Controls
(n = 82)

Age (years)

33 ± 6

31 ± 6

34 ± 7

29 ± 5a

BMI (kg/m )

28.38 ± 2.66

28.58 ± 3.11

29.64 ± 3.12

23.89 ± 2.7

WC (cm)

101 ± 7

99 ± 12

101 ± 6

87 ± 7c

<0.001

FPG (mg/dL)

95 ± 11

95 ± 14

92 ± 10

82 ± 11d

<0.001

TC (mg/dL)

206 ± 44

200 ± 49

210 ± 47

177 ± 32e

<0.001

TG (mg/dL)

188 ± 108

178 ± 91

231 ± 151

130 ± 126f

<0.001

HDL-C (mg/dL)

41 ± 7

41 ± 6

41 ± 7

46 ± 8g

<0.001

LDL-C (mg/dL)

129 ± 36

125 ± 40

130 ± 38

108 ± 30h

0.001

AST (IU/L)

59 ± 22

50 ± 21

43 ± 15

21 ± 5i

<0.001

ALT (IU/L)

123 ± 48

102 ± 47

85 ± 29

20 ± 10j

<0.001

GGT (IU/L)

69 ± 50

69 ± 55

79 ± 77

24 ± 14

<0.001

Urea (mg/dL)

29 ± 7

31 ± 7

28 ± 6

29 ± 6

0.196

BUN (mg/dL)

13.71 ± 3.21

14.34 ± 3.04

13.14 ± 2.89

13.40 ± 2.79

0.194

1.04 ± 0.12

1.05 ± 0.11

1.04 ± 0.14

1.03 ± 0.13

0.826

GFR (mL/min/1.73 m )

89.32 ± 11.95

90.64 ± 12.22

89.71 ± 13.82

91.16 ± 12.01

0.770

Albumin (mg/dL)

4.82 ± 0.25

4.73 ± 0.27

4.74 ± 0.37

4.74 ± 0.25

0.239

Insulin (µU/mL)

16.58 ± 8.05

15.74 ± 9.94

HOMA-IR

2.81 ± 2.48

2.94 ± 2.51

2

Creatinine (mg/dL)
2

P value
<0.001
b

k

<0.001

16.72 ± 10.43

6.67 ± 2.84

l

<0.001

3.61 ± 2.65

1.12 ± 0.75

<0.001

m

Data are expressed as the means ± SD or median (25th–75th interquartile range) as appropriate. P values were calculated using ANOVA
with Bonferroni correction.
NAFLD: nonalcoholic fatty liver disease, BMI: body mass index, WC: waist circumference, FPG: fasting plasma glucose, TC: total
cholesterol, TG: triglyceride, HDL-C: high density lipoprotein cholesterol, LDL-C: low density lipoprotein cholesterol, AST: aspartate
aminotransferase, ALT: alanine aminotransferase, GGT: γ-glutamyltransferase, BUN: blood urea nitrogen, GFR: glomerular filtration
rate, HOMA-IR: homeostasis model of assessment-insulin resistance. Values in bold are significant.
a
P = 0.001 versus NASH, P = 0.003 versus SS; b P < 0.001 versus NASH, Borderline NASH and SS; c P < 0.001 versus NASH, Borderline
NASH and SS;
d
P < 0.001 versus NASH and Borderline NASH, P = 0.001 versus SS; e P < 0.001 versus NASH, P = 0.014 Borderline NASH, P = 0.002
versus SS; f P = 0.007 versus NASH, P < 0.001 versus SS.
g
P < 0.001 versus NASH, P = 0.001 Borderline NASH, P = 0.002 versus SS; h P = 0.002 versus NASH, P = 0.033 Borderline NASH, P
= 0.031 versus SS.
i
P < 0.001 versus NASH, Borderline NASH and SS; j P < 0.001 versus NASH, Borderline NASH and SS; k P < 0.001 versus NASH,
Borderline NASH and SS.
l
P < 0.001 versus NASH, Borderline NASH and SS; m P < 0.001 versus NASH, Borderline NASH and SS.

NAFLD patients were significantly higher than those in
the control cases and also elevated BUN was negatively
correlated with liver/spleen ratio of CT values, ALT, and
AST. Previous investigators concluded that elevated BUN
was related to the RAAS activity and this may be an early
marker in the way of increasing CVD risk in patients with
NAFLD.
In the present study we did not observe any significant
difference regarding the BUN levels between NAFLD

patients and controls. In addition, there was no significant
association of BUN levels with either biochemical
parameters or histopathologic findings, except positive
correlation with TG and TC.
We suggest some possible explanations for the lack
of relationship between BUN levels and NAFLD in our
study. Firstly, it is shown that one of the pathogenetic
mechanisms responsible for the elevation of BUN level
is RAAS activation (17). At the same time, RAAS plays

989

ERÇİN et al. / Turk J Med Sci
Table 4. Comparison of anthropometric and laboratory features of patients with and without fibrosis
Fibrosis 0
(n = 88)

Fibrosis 1–3
(n = 107)

P value

Age (years)

31.6 ± 6.3

32.4 ± 6.4

0.270

BMI (kg/m )

28.8 ± 2.8

28.3 ± 3.2

0.807

WC (cm)

100 ± 6

101 ± 7

0.892

FPG (mg/dL)

95 (86–99)

94 (88–100)

0.969

TC (mg/dL)

198 ± 38

211 ± 42

0.120

TG (mg/dL)

154 (122–220)

168 (123–250)

0.127

HDL-C (mg/dL)

40 (36–41)

42 (37–47)

0.155

LDL-C (mg/dL)

124 ± 32

131 ± 34

0.283

AST (IU/L)

40 (34–51)

51 (39–68)

<0.001

ALT (IU/L)

86 (62–117)

109 (84–135)

0.001

GGT (IU/L)

59 (39–92)

57 (44–76)

0.503

Urea (mg/dL)

29.21 ± 6.31

28.94 ± 6.81

0.508

BUN (mg/dL)

13.64 ± 2.95

13.51 ± 3.18

0.508

1.07 ± 0.12

1.05 ± 0.11

0.456

GFR (mL/min/1.73 m )

88.20 ± 11.64

7.20 ± 1.70

0.171

Albumin (mg/dL)

4.7 ± 0.3

4.8 ± 0.3

0.285

Insulin (µU/mL)

12.2 (9.28–17.05)

15.38 (10.14–20.86)

0.147

HOMA-IR

2.34 (1.68–3.94)

2.97 (2.14–4.95)

0.003

Variable

2

Creatinine (mg/dL)
2

Data are expressed as means ± SD or median (25th–75th interquartile range) as appropriate.
P values were calculated using Student’s t-test and Mann–Whitney U test as appropriate.
BMI: body mass index, WC: waist circumference, FPG: fasting plasma glucose, TC: total cholesterol, TG:
triglyceride, HDL-C: high density lipoprotein cholesterol, LDL-C: low density lipoprotein cholesterol,
AST: aspartate aminotransferase, ALT: alanine aminotransferase, GGT: γ-glutamyltransferase, BUN:
blood urea nitrogen, GFR: glomerular filtration rate, HOMA-IR: homeostasis model of assessmentinsulin resistance.

a key role in hepatic fibrosis (23). In our group 45.1%
of the patients had no fibrosis, while 50.3% had grade 1
fibrosis. Regarding the fibrosis levels, it can be said that
our NAFLD cohort contained subjects with early stages of
the disease. In the future, progressing fibrosis may cause
the elevation of the BUN levels. Secondly, we think that
the lack of relationship between BUN levels and NAFLD
in our cohort could be dependent on the selection criteria
of our study population. Our patients were nondiabetic
and nonhypertensive and we know that both T2DM and
hypertension can cause renal problems and elevation
of BUN levels (27). Thus, NAFLD patients having these
comorbid conditions may have high BUN levels.
Nevertheless, the current study needs to be interpreted
in the context of certain potential limitations. Firstly,
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the cross-sectional design of the study makes causal
interpretations of associations between BUN levels and
NAFLD difficult. Secondly, because of the small number
of patients and the strict inclusion criteria, our findings are
not representative for all subjects with NAFLD. However,
we think that the design of our study was a requirement for
the goals we wanted to achieve. Lastly, all participants were
men, and it remains to be determined if similar findings
would be observed in women.
To summarize, no significant relationship was found
between BUN levels and metabolic and histopathologic
findings of patients with NAFLD. Further investigations
that include patients with late stage NAFLD are required
to confirm this finding.
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